This editorial refers to 'Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo' by C. Iaconetti et al., Pathological remodelling of the blood vessel wall following vascular injury involves a switch in smooth muscle cell (SMC) phenotype, from a differentiated and contractile phenotype to a proliferative and synthetic state, resulting in adventitial and medial remodelling. Although this process is essential during wound healing, dysregulation of this process is central to the aetiology of a number of vascular proliferative pathologies. A substantial research effort has been attributed to trying to determine the underpinning molecular mechanisms which control this phenotypic switch in order to harness novel approaches to prevent prolonged periods of de-differentiation following vascular injury, thereby potentially improving clinical outcome. Recently, a number of studies have demonstrated that small non-coding RNA molecules, microRNAs (miRNAs), play a prominent role in controlling or modulating vascular differentiation and proliferation.
Pathological remodelling of the blood vessel wall following vascular injury involves a switch in smooth muscle cell (SMC) phenotype, from a differentiated and contractile phenotype to a proliferative and synthetic state, resulting in adventitial and medial remodelling. Although this process is essential during wound healing, dysregulation of this process is central to the aetiology of a number of vascular proliferative pathologies. A substantial research effort has been attributed to trying to determine the underpinning molecular mechanisms which control this phenotypic switch in order to harness novel approaches to prevent prolonged periods of de-differentiation following vascular injury, thereby potentially improving clinical outcome. Recently, a number of studies have demonstrated that small non-coding RNA molecules, microRNAs (miRNAs), play a prominent role in controlling or modulating vascular differentiation and proliferation. 1 -5 These miRNAs function by partial or incomplete binding of their so-called seed region to complementary sequences in target genes to cause translational repression or degradation of these genes. This incomplete binding is thought to allow a single miRNA to target multiple mRNAs, which can potentially confer beneficial effects on disease pathogenesis through regulation of multiple genes. Iaconetti et al. 6 provided further evidence that miRNAs play a prominent role in controlling phenotypic modulation of SMCs. The current study demonstrates that miR-23b is down-regulated following vascular injury in a rat model, and that adenovirus-mediated overexpression of miR-23b attenuates neointimal formation following balloon injury. The authors also utilize loss-and gain-of-function approaches to demonstrate that elevation of miR-23b levels reduces SMC proliferation and migration, whereas repression of endogenous miR-23b levels induces the opposite effects. Intriguingly, the authors also demonstrate that these miRNA mimics and inhibitors can enhance or repress the levels of SMC differentiation markers, Acta-2 and Myh11. These findings are further validated by investigating the effect of altering miR-23b levels on myocardin expression, revealing that elevation of miR-23b enhances myocardin expression and knockdown of miR-23b levels induces the opposite effect. Myocardin is an extremely potent serum response cofactor that is selectively expressed in cardiac hypertrophy and SMC, which binds to CArG elements along with the serum response factor to selectively induce expression of all SMC marker genes (a-actin, SM MHC, SM22, and calponin, review by Alexander and Owens 7 ). It is, however, important to note that phenotypic modulation of SMC marker expression in vitro does not always correlate with modulation in vivo, since cells maintained in culture are already highly de-differentiated. However, Iaconetti et al. report that adenovirus-mediated overexpression of miR-23b enhances myocardin and SMC differentiation marker expression and reduced neointimal formation in vivo, although anti-miRNAs directed to miR-23b did not affect neointimal formation in vivo ( Figure 1) . To elucidate the molecular mechanism responsible for these changes, the author investigated known and novel mRNA targets of miR-23b with defined roles in vascular SMC injury [urokinase-type plasminogen activator, SMAD family member 3, and forkhead box O4 (FoxO4)]. These miR-23b targets were all reduced at the mRNA and protein level in injured arteries transduced with the adenovirusesoverexpressing miR-23b, suggesting that their repression may play a role in the beneficial effect mediated by miR-23b overexpression. Further investigation in vitro confirmed that miR-23b mimics repressed these targets and anti-miRNAs enhanced target expression in vascular SMCs.
Vascular injury enhances transforming growth factor-b1 (TGF-b1) and SMAD3 expression, and this process have been reported, among others, in neointimal hyperplasia. TGF-b1/SMAD3 stimulation has been shown to enhance SMC de-differentiation, 8 and SMAD3 has been shown to be a putative target gene of miR-23b in the liver using luciferase reporter assay in vitro. FoxO4 were provided to validate the specificity of this interaction. Previous studies have defined a role of FoxO4 in TNF-a-induced SMC migration following nuclear FoxO4 accumulation and transcriptional activation of MMP-9 through a mechanism which requires an Sp-1 DNA-binding site in the promoter of the MMP-9 gene. 10 The authors go on to demonstrate that TNF-a induced a down-regulation of miR-23b and a reciprocal up-regulation of FoxO4 levels resulting in SMC migration in Boyden chambers in vitro, effects that were enhanced or repressed following treatment with miR-23b inhibitors or mimics,
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respectively. Furthermore, MMP-9 expression was reduced in TNF-a-induced SMC following miR-23b overexpression. These findings are in concordance with the previously published report by Li et al., 10 demonstrating that FoxO4-deficient mice have a reduced capacity to develop neointimal lesions in response to ligation injury. This reduction in neointimal formation in vivo was correlated with a reduction in SMC migration but not in proliferation in response to TNF-a following knockdown of FoxO4 in vitro. As we have mentioned before, the authors go on to demonstrate that knockdown of FoxO4 attenuates the induction of MMP-9 expression in response to TNF-a effects also found in SMC isolated from FoxO4 knockout mice. Innovatively, Iaconetti et al utilize blockers directed at the binding/target site for miR-23b on the 3 ′ UTR of FoxO4 to demonstrate that overexpression of miR-23b was unable to enhance SMC marker gene expression in the presence of these blockers. Furthermore, the authors report that the FoxO4 blocker inhibited the reduction in TNF-a-induced SMC migration following overexpression of miR-23b. However, inhibitors of FoxO4 had no effect on SMC proliferation, suggesting that the reduction in SMC proliferation following overexpression of miR-23b is not mediated by FoxO4. TGF-b is up-regulated at the time of vascular injury and a number of reports have demonstrated that augmentation or inhibition of endogenous TGF-b levels enhances SMC proliferation and neointimal formation in vivo, 11, 12 whereas blocking antibodies attenuated neointimal formation. 13 These findings have always been hard to replicate in vitro since TGF-b profoundly inhibits SMC proliferation in culture. 14 However, a number of recent studies have demonstrated that Smad3, one of the central signal molecules in TGF-b receptor signalling, is also up-regulated following vascular injury, and elevation of Smad3 levels via adenoviral vectors induces SMC proliferative in response to TGF-b in vitro and enhanced neointimal formation in vivo, events that were attenuated following knockdown of Smad3. 15, 16 In contrast to these findings, Kobayashi et al. 17 demonstrated that photochemical injury in Smad3-deficient mice enhanced neointimal formation. There are a number of reasons for these contrasting findings, since TGF-b and Smad3 are known to play distinct roles in endothelial Figure 1 A schematic model of the role microRNA-23b plays in SMC differentiation, migration, and proliferation following vascular injury. Overexpression of miR-23b with adenoviral vectors down-regulates miR-23b targets; uPA, SMAD3, and FoxO4. A reduction in FoxO4 reduces TNF-a-induced SMC migration, possibly through inhibition of MMP-9. Furthermore, up-regulation of miR-23b also enhances myocardin levels and SMC differentiation marker expression. Furthermore, overexpression of miR-23b also inhibits SMC proliferation in a FoxO4-independent mechanism, possibly involving SMAD3 and uPA and neointimal formation following balloon injury in vivo.
Editorial cells and inflammatory cells that play prominent roles in the response to injury. These studies suggest that persistent elevation of Smad3 levels mediates the proliferative response of TGF-b in SMC following vascular injury. Taken together, these studies suggest that overexpression of miR-23b and a subsequent down-regulation of Smad3 may mediate the reduction in SMC proliferation following balloon injury in the recent report by Iaconetti et al. Furthermore, it has been reported that miR-23b is a part of a cluster with miR-27b and miR-24-1, and is co-regulated by the same transcriptional control mechanism. The authors have emphasized the down-regulation of the cluster following injury of carotid arteries with a stronger reduction of miR-23b. Clearly, a potential synergistic effect of all (or other) members of the cluster has not been elucidated. Moreover, the molecular mechanism responsible for the silencing of the cluster after vascular injury remains unknown. This could potentially offer additional beneficial options to prevent neointimal formation.
Taken together, these studies suggest that pharmacological or gene therapy vectors that enhance miR-23b expression may provide a novel therapeutic target to maintain SMC differentiation and reduce SMC proliferation and migration in response to acute vascular injury. However, the problem of delivering agents specifically and at sufficient levels to the vasculature still remains. For example, a major limitation with drug-eluting stent is that they also inhibit wound healing and reendothelialization since the drugs target cell proliferation nonspecifically, events which can lead to late stent thrombosis. Indeed, this limitation may pose a problem following overexpression of miR-23b since a previous report by Wang et al. 18 has reported that overexpression of miR-23b decreased cyclin H levels and endothelial cell proliferation in response to oscillatory shear flow in endothelial cell event that may delay re-endothelialization following acute vascular injury.
A further potential limitation of overexpressing miR-23b, especially in coronary arteries, may be a confounding effect on the myocardium. Previous studies have demonstrated that miR-23 is up-regulated in failing human hearts and overexpression of miR-23a and miR-23b (differ by a single nucleotide) can induce rat myocyte hypertrophy and cardiac hypertrophy in mice in vivo. 19, 20 Although gene transfer can be theoretically localized to the vasculature, the authors did not study whether the endogenous miR-23b or ectopically delivered miRNA was secreted from infected cells. If so, the aforementioned effects on the vascular endothelium and/or myocardium may be relevant. In support of this, a recent report by Ostenfeld et al. 21 demonstrated that some metastatic cancers secrete miR-23b and other miRNAs with tumour suppressor functions. Although Iaconetti et al. report that co-cultures of endothelial cells overexpressing miR-23b do not enhance SMC differentiation markers in Boyden chambers, these studies did not determine whether miR-23b is released per se or whether SMC have the potential to release miR-23b into extracellular vehicles, such as exosomes. Even though we have highlighted the potential for off-target effects following up-regulation of miR-23b, it is possible that overexpression of miR-23b in other cell types involved in the response to injury, such as inflammatory cells, could cause beneficial effect. Indeed, Zhu et al. 22 has previously reported that augmentation of endogenous miR-23b levels in transgenic mice or mice treated with adenovirus vectors to enhance miR-23b levels can reduce inflammatory cytokine expression, via inhibition of NF-kb (IL-1b and TNF-a) and inflammation in a number of different murine models. These findings suggest that local overexpression of miR-23b in the vessel wall prior to injury may reduce SMC proliferation and possibly the level of inflammation; however, further detailed study in lineage-specific mice or bone marrow chimeras would be necessary to evaluate this possibility. In summary, this study adds to the growing literature defining the importance of certain miRNA in the response of the vasculature to injury. It would be prudent to ascertain whether this miRNA was modulated in other species and more complex and clinically relevant models. It is without doubt that miRNA therapeutics might offer novel approaches to the treatment of vascular proliferative pathologies where targeting SMC phenotypic switch might be beneficial.
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